Babler Martin 4

What Happened

• Martin Babler, a director of Prelude Therapeutics (PRLD), was granted an option award covering 38,000 shares on June 9, 2026. The grant is reported as a derivative award at $0 (no cash paid) — this was a grant/award, not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely).
• Transaction type/code: Award/Grant (A), derivative.
• Shares involved: 38,000 option shares; acquisition price reported $0; aggregate acquisition value $0.
• Shares owned after transaction: Not disclosed in the supplied filing.
• Footnote: The option award vests in full upon the earlier of (a) the issuer’s next annual stockholder meeting or (b) the one-year anniversary of the grant date, provided the reporting person continues service on each vesting date.

Context

• This was a grant of options (a derivative award), not an exercise or sale. Options do not create immediate proceeds until exercised and typically vest over time; the noted vesting condition requires continued service. Director grants are common as compensation; the filing is factual and does not in itself indicate intent to buy or sell additional stock.